Skip to content
LATEST
Health

Soligenix posts Phase 2 psoriasis trial results

The topical Hypericin study covered mild-to-moderate plaque psoriasis, adding a public registry marker for Soligenix’s dermatology pipeline.

Soligenix posts Phase 2 psoriasis trial results

Soligenix completed a Phase 2 clinical trial of topical Hypericin for mild-to-moderate plaque psoriasis, with results posted on ClinicalTrials.gov on Nov. 17, the clinical registry showed.

The posting matters because Phase 2 trials test whether a treatment merits larger studies; this record gives researchers and clinicians a public source to review for the psoriasis program.

The trial is listed under the record title “Topical SGX302 for Mild-to-Moderate Psoriasis” and carries the ClinicalTrials.gov identifier NCT05442190. The source identifies the condition as mild-to-moderate plaque psoriasis and the intervention as topical Hypericin.

The available information does not establish whether topical Hypericin improved plaque psoriasis or how it compared with another treatment or placebo.

For readers, the main point is procedural rather than clinical: a completed Phase 2 psoriasis trial now has results available for professional review. Any assessment of benefit or risk depends on the detailed registry results and later peer-reviewed or regulatory materials, if released.

Source: clinical registry, ClinicalTrials.gov, Nov. 17, 2026.

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news